10-Q: Actinium Pharmaceuticals Reports Q1 2025 Results, Highlights Clinical Pipeline Advancements

Actinium Pharmaceuticals reports its Q1 2025 financial results and provides an update on its clinical development programs, including Actimab-A, Iomab-ACT, and ATNM-400.

Summary

• Actinium Pharmaceuticals reported a net loss of $15.9 million for the three months ended March 31, 2025, compared to a net loss of $8.7 million for the same period in 2024.
• Research and development expenses increased to $7.7 million from $6.6 million year-over-year, while general and administrative expenses rose to $8.9 million from $3.0 million.
• The company's cash and cash equivalents totaled $65.3 million as of March 31, 2025, down from $72.9 million at the end of 2024.
• Actinium is advancing its clinical pipeline, including Actimab-A in myeloid malignancies and solid tumors, Iomab-ACT for cell and gene therapy conditioning, and ATNM-400 for prostate cancer.
• A Phase 2/3 trial for Actimab-A in combination with CLAG-M in relapsed/refractory AML is planned, with the Phase 2 portion expected to begin in the second half of 2025.
• The first patient was enrolled in the Iomab-ACT commercial CAR-T trial in May 2025.
• Preclinical data for ATNM-400, a novel Ac-225-based radiotherapy for prostate cancer, was presented at the AACR annual meeting, demonstrating promising efficacy compared to Pluvicto.
• The company is seeking a strategic partner for Iomab-B to conduct an additional clinical trial based on FDA feedback.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's progress in the clinical pipeline and promising preclinical data, the increased net loss and need for additional trials for Iomab-B temper the positive aspects. The search for a strategic partner also introduces uncertainty.

Positives

• Actinium is advancing its clinical pipeline with multiple ongoing and planned trials for Actimab-A, Iomab-ACT, and ATNM-400.
• The company has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for Actimab-A development, potentially reducing costs.
• Preclinical data for ATNM-400 is promising, showing greater efficacy than Pluvicto in prostate cancer models.
• The first patient was enrolled in the Iomab-ACT commercial CAR-T trial, marking progress in the targeted conditioning program.
• Actinium has multiple isotope supply agreements and qualified vendors in place to supply isotopes for its active and planned clinical trials.

Negatives

• The company reported a larger net loss in Q1 2025 compared to Q1 2024.
• Cash reserves are decreasing.
• The FDA determined that the SIERRA trial alone is not adequate to support a BLA filing for Iomab-B, requiring an additional clinical trial.
• Actinium is seeking a strategic partner for Iomab-B, indicating a need for external funding or collaboration to advance the program.

Risks

• Clinical trials may not demonstrate the efficacy and safety of product candidates.
• Regulatory approvals may be delayed or not obtained.
• The company may face competition from other biotechnology and pharmaceutical companies.
• Product candidates may cause undesirable side effects.
• The company is dependent on key personnel.
• The company may face difficulties in managing growth.
• The company is subject to risks associated with litigation and claims.
• The company's ability to utilize net operating loss carryforwards may be limited.
• The company is dependent on third-party manufacturers and suppliers.
• The company may be subject to claims that its third-party service providers, consultants or current or former employees have wrongfully used or disclosed confidential information of third parties.

Future Outlook

Actinium expects its existing resources will be sufficient to fund its planned operations for more than 12 months following the date of the report and anticipates initial clinical data from the Actimab-A, Venetoclax & ASTX-727 Frontline AML Triplet Phase 1b Combination Trial in second half of 2025.

Management Comments

• The Compensation Committee intends to conduct an analysis of our equity compensation plan and develop an equity compensation strategy that satisfies the purpose of the 2019 Plan to attract and retain the best available personnel who can make meaningful contributions towards achieving our business objectives.

Industry Context

The report highlights Actinium's focus on targeted radiotherapies, a growing area in cancer treatment. The mention of Pluvicto's $1.39 billion in sales underscores the commercial potential of targeted radiopharmaceuticals. Actinium's ATNM-400 aims to address unmet needs in prostate cancer, potentially competing with or complementing existing therapies.

Comparison to Industry Standards

• The report mentions Pluvicto (Lu-177-PSMA-617) marketed by Novartis, which generated sales of $1.39 billion in 2024, as a benchmark for targeted radiotherapy in prostate cancer.
• Actinium's ATNM-400 is differentiated from Pluvicto by targeting a different marker than PSMA and using the alpha-particle emitter Ac-225, potentially leading to fewer off-target effects.
• The company is also developing Iomab-ACT as conditioning for cell and gene therapies, aiming to improve patient access and outcomes compared to current chemotherapy-based regimens.
• The company is seeking to replace current chemotherapy conditioning regimens with Iomab-ACT to provide patients better access to CAR-T.

Legal Proceedings

• A putative class action complaint (the Securities Complaint) was filed against the Company and executives alleging material misrepresentations and omissions concerning the Iomab-B Phase 3 Sierra Trial.
• A derivative shareholder complaint (the Derivative Complaint) was filed against the Company and certain of the Companys directors and officers alleging derivative liability for the allegations made in the Securities Complaint.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees experienced a workforce optimization that reduced headcount by approximately fourteen percent.
• Patients may benefit from the advancement of Actinium's clinical pipeline and potential new treatment options.
• The company's financial performance and strategic decisions impact its suppliers and creditors.

Next Steps

• Initiate the Phase 2 portion of the Actimab-A + CLAG-M pivotal Phase 2/3 trial in the second half of 2025.
• Continue clinical trials for Iomab-ACT, including the commercial CAR-T trial and the sickle cell disease trial.
• Continue to study and advance ATNM-400, with additional data expected in mid-2025.
• Seek a strategic partner for Iomab-B to conduct an additional clinical trial based on FDA feedback.
• Commence the build-out of a manufacturing facility in the second half of 2025.

Key Dates

Keywords

Actinium Pharmaceuticals, Iomab-B, Actimab-A, ATNM-400, Iomab-ACT, clinical trials, radiotherapy, AML, prostate cancer, CAR-T therapy, FDA, Ac-225, CD33, CD45, SIERRA trial, financial results